FCA Price Walking Ban 🇬🇧

On July 13, 2021, Akur8, the next generation automated insurance pricing solution, and Munich RE Consulting, pioneering advisor for the transformation of the insurance sector, hosted a webinar to shed some light on the FCA’s (Financial Conduct Authority) price walking ban. Interesting insights were shared regarding the potential market impact of the new regulation, and the expected changes that insurers will have to implement on their pricing processes to be compliant. What is the new FCA rule? FCA is the conduct regulator for 51,000 financial services firms and financial markets in the UK. It is responsible for regulating the broad financial sector, enhancing the integrity of the UK financial system, and promoting effective and fair competition in the interest of consumers, including shielding them from unfair discrimination. The FCA’s new price walking ban rule was designed to do just that. Indeed, according to the FCA, 6 million insurance policyholders in the UK are currently paying what is referred to as a “loyalty penalty”, whereby insurers charge higher premiums to their existing customers, than the rates offered to new customers being acquired. From January 1, 2022, this market practice will have to come to an end. Insurance companies will no longer be able to charge higher premiums to existing customers compared to new customers. The FCA stepping in to implement such new insurance pricing regulation in one of Europe’s more deregulated insurance markets is a pretty significant move that is insightful for the UK insurance market and beyond.
Cover of Akur8's white paper "FCA Price Walking Ban"
Fill up the form to receive this white paper
Fill up the form to receive this report
TERMS OF USE OF THE PAPER “ANALYSIS OF AKUR8 PRICING SOLUTION AND METHODOLOGY” (“Terms of Use”)

In the context of Akur8’s and Milliman’s strategic alliance to provide AI-driven pricing solutions to insurers, Akur8 has engaged Milliman to analyse Akur8’s pricing solution and methodology (“Akur8 Tool”). Milliman’s Paper “Analysis of Akur8 pricing solution and methodology” (the “Paper”) provides a general opinion on the relevance of the modelling choices made by the Akur8 Tool in the context of non-life insurance pricing.Milliman is hereafter referred to as “we” and the readers of the Paper as “you”.

RESTRICTIONS
Distribution
You are not allowed to distribute or disclose all or part of the Paper to any third party whatsoever, without Milliman’s prior written consent, which may be given at their sole discretion.No Use of Milliman nameYou agree not to use and/or refer to Milliman’s name and/or trademarks directly or indirectly in any communication with any third party without Milliman’s prior written consent, which consent shall be required for each use or disclosure and shall be granted only at Milliman’s sole discretion.

RESERVATION
Absence of Commitment
Any judgement on the elements contained in the Paper should be made only after studying the document in its entirety. Any conclusions drawn from one or more sections taken in isolation may be incorrect.The Paper is intended to be used by persons with certain levels of expertise in the areas covered and for the purposes stated. Any reader of the Paper should have a certain level of expertise in the areas related to this analysis, in order to appreciate the significance of the assumptions made and the impact of those assumptions on the results obtained.We recommend that any reader be assisted in reviewing the Paper by a qualified professional to ensure that our findings and recommendations have been understood.The Paper has been commissioned by and prepared for the exclusive use of Akur8, in accordance with the terms of our engagement letter. We make no commitment to third parties and shall not be liable for any use by a third party of an opinion or more generally for the use by such third party of the results included in the Paper. Milliman does not intend to benefit or create any legal obligation to any third-party recipient of its work. 
Intellectual Property
Any right not expressly granted to you in these Terms of Use remains the right of Milliman and Akur8. Using the Paper under the conditions set forth in the section “Restrictions” does not give you ownership of any intellectual property rights in the content you access (including any branding used in the Paper)
By submitting this form, I agree to the terms of use and the privacy policy.
Thank you! Your form has been received and we will get back to you shortly!
Oops! Something went wrong while submitting the form. Please try again.
TERMS OF USE OF THE PAPER “ANALYSIS OF AKUR8 PRICING SOLUTION AND METHODOLOGY” (“Terms of Use”)

In the context of Akur8’s and Milliman’s strategic alliance to provide AI-driven pricing solutions to insurers, Akur8 has engaged Milliman to analyse Akur8’s pricing solution and methodology (“Akur8 Tool”). Milliman’s Paper “Analysis of Akur8 pricing solution and methodology” (the “Paper”) provides a general opinion on the relevance of the modelling choices made by the Akur8 Tool in the context of non-life insurance pricing.Milliman is hereafter referred to as “we” and the readers of the Paper as “you”.

RESTRICTIONS
Distribution
You are not allowed to distribute or disclose all or part of the Paper to any third party whatsoever, without Milliman’s prior written consent, which may be given at their sole discretion.No Use of Milliman nameYou agree not to use and/or refer to Milliman’s name and/or trademarks directly or indirectly in any communication with any third party without Milliman’s prior written consent, which consent shall be required for each use or disclosure and shall be granted only at Milliman’s sole discretion.

RESERVATION
Absence of Commitment
Any judgement on the elements contained in the Paper should be made only after studying the document in its entirety. Any conclusions drawn from one or more sections taken in isolation may be incorrect.The Paper is intended to be used by persons with certain levels of expertise in the areas covered and for the purposes stated. Any reader of the Paper should have a certain level of expertise in the areas related to this analysis, in order to appreciate the significance of the assumptions made and the impact of those assumptions on the results obtained.We recommend that any reader be assisted in reviewing the Paper by a qualified professional to ensure that our findings and recommendations have been understood.The Paper has been commissioned by and prepared for the exclusive use of Akur8, in accordance with the terms of our engagement letter. We make no commitment to third parties and shall not be liable for any use by a third party of an opinion or more generally for the use by such third party of the results included in the Paper. Milliman does not intend to benefit or create any legal obligation to any third-party recipient of its work. 
Intellectual Property
Any right not expressly granted to you in these Terms of Use remains the right of Milliman and Akur8. Using the Paper under the conditions set forth in the section “Restrictions” does not give you ownership of any intellectual property rights in the content you access (including any branding used in the Paper)
By submitting this form, I agree to the terms of use and the privacy policy.
Thank you! Your request has been received and we will send you the report within 24 hours.
Oops! Something went wrong while submitting the form. Please try again.